![John Bell](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
John Bell
Chairman at IMMUNOCORE HOLDINGS PLC
Net worth: 422 124 $ as of 2025-06-29
Profile
John Irving Bell founded The Wellcome Trust Centre for Human Genetics in 1993 and Oxagen Ltd. in 1997, where he worked as Non-Executive Director from 1997 to 2017.
Dr. Bell also founded Powderject Pharmaceuticals Plc, where he worked as Director and Avidex Ltd., where he worked as Independent Non-Executive Director.
Dr. Bell also currently works at Ellison Institute of Technology, as Co-Chief Executive Officer from 2024, Oxford Centre for Diabetes Endocrinology & Metabolism, as Chairman-Partnership Board from 1999, The Oxford Health Alliance, as Chairman, GMEC Management Co. Ltd., as Chairman, Office for Strategic Co-ordination of Health Research, as Chairman, Immunocore Holdings Plc, as Chairman, The Jenner Institute Laboratories, as Non-Executive Director from 2013, Oxford University Hospitals NHS Trust, as Non-Executive Director, The Gray Laboratory Cancer Research Trust, as Non-Executive Director, Genomics England Ltd., as Non-Executive Director, Oxford Science Enterprises PLC, as Non-Executive Director, Rhodes Trust, as Trustee, The Ewelme Almshouse Charity, as Trustee, Biospring Management Partners LP, as Advisor, and Our Future Health Uk, as Trustee.
Dr. Bell also formerly worked at Arcturis Data Ltd., as Chairman, Genentech, Inc., as Director, Roche Holding AG, as Non-Executive Director from 2011 to 2020, F.
Hoffmann-La Roche Ltd., as Non-Executive Director, Atopix Therapeutics Ltd., as Director, the University of Oxford, as Professor from 2002 to 2024, and Academy of Medical Sciences, as President from 2006 to 2011.
Dr. Bell received his doctorate degree in 1990 from Magdalen College School Oxford Ltd, undergraduate degree in 1979 from Magdalen College School Oxford Ltd, and undergraduate degree in 1975 from the University of Alberta.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2025-05-14 | 13,452 ( 0.03% ) | 422 124 $ | 2025-06-29 |
Latest news about John Bell
John Bell active positions
| Companies | Position | Start |
|---|---|---|
| IMMUNOCORE HOLDINGS PLC | Chairman | - |
The Ewelme Almshouse Charity | Director/Board Member | - |
Our Future Health Uk
 Our Future Health Uk Miscellaneous Commercial ServicesCommercial Services Our Future Health UK is a collaboration between the public, private, and charity sectors. Our Future Health UK is a member of the UK Health Data Research Alliance, which establishes best practices for the ethical use of UK health data for research at scale. The private company is based in Manchester, UK. The British company aims to be the largest health research program in the UK, bringing people together to develop new ways to prevent, detect, and treat diseases. The company is committed to protecting participants' confidentiality while maximizing the opportunity to help researchers tackle serious diseases. The CEO of the company is Andrew Roddam. | Director/Board Member | - |
Oxford Science Enterprises PLC
 Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom. | Director/Board Member | - |
Biospring Management Partners LP
 Biospring Management Partners LP Investment ManagersFinance Biospring Management Partners LP (Biospring Partners) is a venture capital firm founded in 2020 by Michelle Dietwiler and Jennifer Lumba. The firm is headquartered in New York. | Consultant / Advisor | - |
Office for Strategic Co-ordination of Health Research | Chairman | - |
Genomics England Ltd.
 Genomics England Ltd. Miscellaneous Commercial ServicesCommercial Services Genomics England Ltd. runs and delivers 100,000 genomes project. Its flagship project sequences 100,000 genomes from NHS patients with a rare disease and their families, and patients with cancer. The company was founded by Jeremy Hunt on July 5, 2013 and is headquartered in London, the United Kingdom. | Director/Board Member | - |
Rhodes Trust | Director/Board Member | - |
GMEC Management Co. Ltd. | Chairman | - |
| ░░░ ░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░ | - |
Former positions of John Bell
| Companies | Position | End |
|---|---|---|
| ░░░░░░░░░░ ░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░ ░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░ ░░░░░░░ ░░░░░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
Training of John Bell
Magdalen College School Oxford Ltd | Doctorate Degree |
University of Alberta | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| ROCHE HOLDING AG | Health Technology |
| SENSYNE HEALTH PLC | Commercial Services |
| IMMUNOCORE HOLDINGS PLC | Health Technology |
| Private companies | 21 |
|---|---|
Avidex Ltd.
 Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | Health Technology |
Academy of Medical Sciences
 Academy of Medical Sciences Miscellaneous Commercial ServicesCommercial Services The Academy of Medical Sciences was founded in 1998 and provides biomedical and health research services. The non-profit company is based in London, UK. | Commercial Services |
Genentech, Inc.
 Genentech, Inc. Pharmaceuticals: MajorHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Health Technology |
Oxford Centre for Diabetes Endocrinology & Metabolism | |
Oxagen Ltd.
 Oxagen Ltd. Pharmaceuticals: MajorHealth Technology Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom. | Health Technology |
The Wellcome Trust Centre for Human Genetics | |
Oxford University Hospitals NHS Trust | Miscellaneous |
The Gray Laboratory Cancer Research Trust | |
The Jenner Institute Laboratories
 The Jenner Institute Laboratories Miscellaneous Commercial ServicesCommercial Services The Jenner Institute Laboratories engages in the development of vaccine against major diseases. The company was founded in November 2005 and is headquartered in Oxford, the United Kingdom. | Commercial Services |
The Oxford Health Alliance
 The Oxford Health Alliance Miscellaneous Commercial ServicesCommercial Services The Oxford Health Alliance is a British charitable company that focuses on preventing chronic diseases. The non-profit company is based in Greater London, UK. | Commercial Services |
GMEC Management Co. Ltd. | |
Rhodes Trust | |
The Ewelme Almshouse Charity | |
Atopix Therapeutics Ltd.
 Atopix Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Atopix Therapeutics Ltd. develops medicines to treat atopic dermatitis and severe asthma. The firm also assess the safety and pharmacokinetic profile of its back-up molecule ATX2417 in a phase I study. The company was incorporated on October 10, 2012 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Genomics England Ltd.
Genomics England Ltd. Miscellaneous Commercial ServicesCommercial Services Genomics England Ltd. runs and delivers 100,000 genomes project. Its flagship project sequences 100,000 genomes from NHS patients with a rare disease and their families, and patients with cancer. The company was founded by Jeremy Hunt on July 5, 2013 and is headquartered in London, the United Kingdom. | Commercial Services |
Office for Strategic Co-ordination of Health Research | |
Powderject Pharmaceuticals Plc
 Powderject Pharmaceuticals Plc Medical SpecialtiesHealth Technology Powderject Pharmaceuticals Plc develops pharmaceutical products. It offers researching, developing, manufacturing and marketing for existing and next generation vaccines. The company was founded in 1993 and is located in Oxford, UK | Health Technology |
Biospring Management Partners LP
Biospring Management Partners LP Investment ManagersFinance Biospring Management Partners LP (Biospring Partners) is a venture capital firm founded in 2020 by Michelle Dietwiler and Jennifer Lumba. The firm is headquartered in New York. | Finance |
Oxford Science Enterprises PLC
Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom. | Finance |
Our Future Health Uk
Our Future Health Uk Miscellaneous Commercial ServicesCommercial Services Our Future Health UK is a collaboration between the public, private, and charity sectors. Our Future Health UK is a member of the UK Health Data Research Alliance, which establishes best practices for the ethical use of UK health data for research at scale. The private company is based in Manchester, UK. The British company aims to be the largest health research program in the UK, bringing people together to develop new ways to prevent, detect, and treat diseases. The company is committed to protecting participants' confidentiality while maximizing the opportunity to help researchers tackle serious diseases. The CEO of the company is Andrew Roddam. | Commercial Services |
- Stock Market
- Insiders
- John Bell
